Other relevant news · Page 9 · Mind Medicine Australia
Mind Medicine Australia logo Menu

Other relevant news

Could mushrooms, molly and acid be the new wave of mental health care?

NBC News, October 13, 2021

Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.

What if a Pill Can Change Your Politics or Religious Beliefs?

Scientific American, October 11, 2021

A new mental health treatment using the psychedelic compound psilocybin raises questions about medicine and values.

National anxiety crisis worsens

The Australian, October 3, 2021

Australians are reporting depression, anxiety and stress at higher rates than the same time last year, with four in five experiencing poor mental health, and children and young people the most seriously affected, as pandemic uncertainty and lockdowns continue to take a toll.

Psychedelic biotech Psylo raises first funds

The Australian, October 1, 2021

There’s a growing pool of funds being invested in psychedelic research.

Psychedelics might reduce internalized shame and complex trauma symptoms in those with a history of childhood abuse

Psypost, September 30, 2021

The use of psychedelic medicines is associated with lower levels of complex posttraumatic stress symptoms and internalized shame in adults who suffered maltreatment in childhood, according to new research published in the journal Chronic Stress.

Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac

Newsweek, September 22, 2021

Psilocybin could be the biggest advance since Prozac.

Small pharma successfully completes phase 1 clinical trial of DMT in combination with supportive psychotherapy

Small Pharma, September 21, 2021

Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers.

Medicinal cannabis company Little Green Pharma gets green light for psychedelic drug production

ABC News, September 10, 2021

A WA-based medicinal cannabis company has been given regulatory approval to produce psilocybin, a hallucinogenic substance found in magic mushrooms, to supply for medical research.

The worldview-changing drugs poised to go mainstream

BBC, September 7, 2021

Our Ambassador Dr Rick Doblin (USA) is featured in this article by the BBC: The worldview-changing drugs poised to go mainstream.

Suicide line records highest number of calls in history

The Australian, August 20, 2021

Australia’s biggest suicide support line has recorded the most calls for help it has ever received in one day, amid concerns about long-term mental health consequences of Covid-19 restrictions.

TGA appoints Independent Expert Panel on MDMA and psilocybin

TGA, August 5, 2021

The Therapeutic Goods Administration (TGA) Scheduling Delegate (decision maker) has deferred the final decision on applications to down-schedule MDMA and psilocybin from schedule 9 (prohibited drug) to schedule 8 (controlled drug) pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances. The Independent Expert Panel to undertake this review has now been established.

Canadians Overwhelmingly Support Legal Access to Psilocybin-Assisted Therapy, Poll Reveals

Psilocybin Alpha, August 4, 2021

A new poll, commissioned by the Canadian Psychedelic Association, has highlighted widespread support for legal access to psilocybin-assisted therapy among Canadians.

New Yale Study Shows Psilocybin Spurs Growth of Neural Connections Lost in Depression

Microdose.buzz, August 3, 2021

A new study conducted by researchers at Yale University showed psilocybin can facilitate the regrowth of neurons lost in depression.

Just One Dose of Magic Mushroom Compound Regrows Lost Brain Connections in Mice

Science Alert, July 6, 2021

Psilocybin, the active psychedelic compound, has some curious effects on the human brain.

Psychedelic IPOs build momentum as Atai Life Sciences goes public

PitchBook, June 18, 2021

Making its Wall Street debut, Peter Thiel-backed Atai Life Sciences has become the third biotech company focused on psychedelic treatment for mental health disorders to list on a major US stock exchange.

My team’s research shows magic mushrooms treat depression, but undoing the stigma will be a bigger challenge

iNews, June 3, 2021

Bringing psychedelic therapy into mainstream treatment will present some major challenges.

Magic mushroom microdosing: Sick Kiwis call for ‘life-saving’ Class-A drug to be legalised

Newshub, May 29, 2021

Every day Kiwis with devastating illnesses are turning to small doses of psychedelics to find relief and are calling for what they call a ‘life-saving’ treatment to be made legal for medical purposes.

Ketamine a game changer in treating eating disorders

Toronto Sun, May 29, 2021

Ketamine, MDMA and psilocybin are proving useful with treatment-resistant mental illnesses, including eating disorders.

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Globe News Wire, May 27, 2021

Algernon recently established a clinical research program for the treatment of stroke focused on DMT.

Could the ‘spirit molecule’ be a treatment option for stroke?

Vancouver Sun, May 25, 2021

Researchers have spent decades and billions of dollars unsuccessfully searching for novel treatments for stroke. Now a Vancouver-based company is putting a unique hypothesis to the test.

Subscribe to our newsletter

Stay in touch with Mind Medicine Australia:

×